Dr. Matthew Lunning, DO
Claim this profileUniversity of Nebraska Medical Center
Studies Lymphoma
Studies B-Cell Lymphoma
12 reported clinical trials
37 drugs studied
Area of expertise
1Lymphoma
BCL6 positive
CCND1 positive
t(11;14) positive
2B-Cell Lymphoma
CCND1 positive
t(11;14) positive
MYC positive
Affiliated Hospitals
Clinical Trials Matthew Lunning, DO is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
Cell Therapy
for Non-Hodgkin's Lymphoma
This trial tests a new treatment where a patient's own immune cells are enhanced to fight difficult-to-treat lymphoma. It targets patients whose cancer hasn't responded to at least two other treatments. The modified cells aim to better recognize and attack the cancer. This new method improves the ability of the patient's immune cells to find and destroy cancer cells.
Recruiting1 award Phase 219 criteria
More about Matthew Lunning, DO
Clinical Trial Related3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Matthew Lunning, DO has experience with
- Cyclophosphamide
- Prednisone
- Doxorubicin
- Rituximab
- Vincristine
- Etoposide
Breakdown of trials Matthew Lunning, DO has run
Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Lunning, DO specialize in?
Matthew Lunning, DO focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved BCL6 positive patients, or patients who are CCND1 positive.
Is Matthew Lunning, DO currently recruiting for clinical trials?
Yes, Matthew Lunning, DO is currently recruiting for 6 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Matthew Lunning, DO has studied deeply?
Yes, Matthew Lunning, DO has studied treatments such as Cyclophosphamide, Prednisone, Doxorubicin.
What is the best way to schedule an appointment with Matthew Lunning, DO?
Apply for one of the trials that Matthew Lunning, DO is conducting.
What is the office address of Matthew Lunning, DO?
The office of Matthew Lunning, DO is located at: University of Nebraska Medical Center, Omaha, Nebraska 10065 United States. This is the address for their practice at the University of Nebraska Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.